Localized immunosuppression in the cardiac allograft induced by a new liposome-mediated IL-10 gene therapy

Journal of Heart and Lung Transplantation

Volumn 21, Issue 11, 2002, Pages 1188-1200

  Hong, Yoo Sun ^a   Laks, Hillel ^a   Cui, Guanggen ^a,b   Chong, Terry ^a   Sen, Luyi ^a,b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DRUG CARRIER; GAMMA INTERFERON; INTERLEUKIN 2; LIPOSOME; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DONOR; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; GENE THERAPY; GRAFT REJECTION; GRAFT SURVIVAL; HEART GRAFT; HEART TRANSPLANTATION; HYPOTHERMIA; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; TH1 CELL; XENOTRANSPLANTATION;

ANIMALS; DRUG CARRIERS; ETHERS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNE TOLERANCE; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; LIPOSOMES; QUATERNARY AMMONIUM COMPOUNDS; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TH1 CELLS; TRANSFECTION; TRANSPLANTATION TOLERANCE;

EID: 0036846830     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)00417-5     Document Type: Article

References (32)

1. Wood K.J. Induction of tolerance to cardiac allografts. Curr Opin Cardiol. 11:1996;208-213.
2. DeBruyne L.A., Li K., Chan S.Y., Qin L., Bishop D.K., Bromberg J.S. Lipid-mediated gene transfer of viral IL-10 prolongs vascularized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses. Gene Ther. 5:1998;1079-1087.
3. Brauner R., Nonoyama M., Laks H., et al. Intracoronary adenovirus-mediated transfer of immunosuppressive cytokine gene prolongs allograft survival. J Thorac Cardiovasc Surg. 114:1997;923-933.
4. Brauner R., Wu L., Laks H., et al. Intracoronary gene transfer of immunosuppressive cytokines to cardiac allografts method and efficacy of adenovirus-mediated transduction . J Thorac Cardiovasc Surg. 13:1997;1059-1067.
5. Wang Q., Finer M.H. Second generation adenovirus vectors. Nature Med. 2:1996;714-716.
6. Thierry A.R., Rabinovich P., Peng B., Mahan L.C., Bryant J.L., Gallo R.C. Characterization of liposome-mediated gene delivery expression, stability and pharmacokinetics of plasmid DNA . Gene Ther. 4:1997;226-237.
7. Stephan D.J., Yang Z.Y., San H., et al. A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo. Hum Gene Ther. 7:1996;1803-1812.
8. Felgner J.H., Kumar R., Sridar C.N., et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulation. J Biol Chem. 269:1994;1550-1561.
9. Dallman M.J., Larson C.P., Moriris P.J. Cytokine gene transcription in vascularised organ grafts analysis using semiquantitative polymerase chain reaction . J Exp Med. 174:1991;493-496.
10. Hoffen E.V., Wichen D.V., Stuij I., et al. In situ expression of cytokines in human heart allografts. Am J Pathol. 149:1996;1991-2003.
11. Egilmez N.K., Iwanuma Y., Bankert R.B. Evaluation and optimization of different cationic liposome formulation for in vivo gene transfer. Biochem Biophy Res Commun. 221:1996;169-173.
12. Li J.J., Ueno H., Pan Y., et al. Percutaneous transluminal gene transfer into canine myocardium in vivo by replication-defective adenovirus. Cardiovasc Res. 30:1995;97-105.
13. Engelhardt J.F., Litzky L., Wilson J.M. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther. 5:1994;1217-1229.
14. Prince H.M. Gene transfer a review of methods and applications . Pathology. 30:1998;335-347.
15. Groux H., Bigler M., de Vries J.E., Roncarolo M.G. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med. 184:1996;19-23.
16. Enk A.H., Angeloni V.L., Udey M.C., Katz S.I. Inhibition of Langerhans cell antigen-presenting function by IL-10 a role for IL-10 in induction of tolerance . J Immunol. 151:1993;2390-2398.
17. Del P.G., De C.M., Almerigogna F., Giudizi M.G., Biagiotti R., Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol. 150:1993;353-360.
18. O'Garra A., Chang R., Go N., Hastings R., Haughton G., Howard M. Ly-1 B (B-1) cells are the main source of B-cell-derived IL-10. Eur J Immunol. 22:1992;711-717.
19. Enk A.H., an Katz S.I. Identification and induction of keratinocyte-derived IL-10. J Immunol. 149:1992;92-95.
20. Turner D., Grant S.C.D., Yonan N., et al. Cytokine gene polymorphism and heart transplant rejection. Transplantation. 64:1997;776-779.
21. Li W., Fu F., Lu L., et al. Systemic administration of anti-interleukin-10 antibody prolongs organ allograft survival in normal and presensitized recipients. Transplantation. 66:1998;1587-1596.
22. Chernoff A.E., Granowitz E.V., Shapiro L., et al. A randomized, controlled trial of IL-10 in human inhibition of inflammatory cytokine production and immune responses . J Immunol. 154:1995;5492-5497.
23. Milddleton P.G., Taylor P.R.A., Jackson G., Proctor S.J., Dickinson A.M. Cytokine gene polymorphisms associating with severe acute grafts-versus-host disease in HLA-identical sibling transplants. Blood. 92:1998;3943-3948.
24. Holler E.M., Roncarolo M.G., Hintermeier-Knable R. Low incidence of transplant-related complications in patients with high spontaneous cellular IL-10 production prior to conditioning evidence for a protective role of IL-10 in allo-genic BMT . Annual meeting of the EBMT:1994.
25. Qian S., Li W., Li Y., et al. Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation. 62:1996;1709-1714.
26. + T cells. J Immunol. 160:1998;3188-3193.
27. Ding L., Linsley P.S., Huang L.Y., Germain R.N., Shevach E.M. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol. 151:1993;1224-1234.
28. Cassatella M.A., Meda L., Bonora S., Ceska M., Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide . J Exp Med. 174:1993;2207-2211.
29. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., De Vries V.J. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes an autoregulatory role of IL-10 produced by monocytes . J Exp Med. 174:1991;1209-1220.
30. Matsuda M., Salazar F., Petersson M., et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cell and downregulates HLA class I expression. J Exp Med. 180:1994;2371-2376.
31. Bejarano M.T., de Waal Malefyt R., Abrams J.S., et al. Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell response generated in primary mixed lymphocyte cultures. Int Immunol. 4:1992;1389-1397.
32. Tanaka J., Imamura M., Kasa M., et al. The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease. Bone Marrow Transplant. 19:1997;571-576.